Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses
CONTENTS

Introduction .................................................................1
Purpose .................................................................2
Methods .................................................................2
Dengue and Zika Virus Epidemiology and Clinical Manifestations ....2
Dengue and Zika Virus Infections and Immune Response ..........2
Dengue and Zika Virus Diagnostic Testing.........................3
Clinical and Epidemiologic Criteria for Testing...................4
Recommended Testing for Symptomatic Nonpregnant Patients ......4
Recommended Testing for Symptomatic Pregnant Women ..........6
Management of Patients with Dengue or Zika Virus Infection .......8
Reporting Dengue and Zika Virus Disease Cases ....................8
References ...............................................................8
Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses

Tyler M. Sharp, PhD1; Marc Fischer, MD1; Jorge L. Muñoz-Jordán, PhD1; Gabriela Paz-Bailey, MD, PhD1; J. Erin Staples, MD, PhD1; Christopher J. Gregory, MD1; Stephen H. Waterman, MD1

1Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Summary

Dengue and Zika viruses are closely related mosquitoborne flaviviruses with similar transmission cycles, distribution throughout the tropics and subtropics, and disease manifestations including fever, rash, myalgia, and arthralgia. For patients with suspected dengue or Zika virus disease, nucleic acid amplification tests (NAATs) are the preferred method of diagnosis. Immunoglobulin M (IgM) antibody testing can identify additional infections and remains an important tool for the diagnosis of these diseases, but interpreting the results is complicated by cross-reactivity, and determining the specific timing of infection can be difficult. These limitations are a particular challenge for pregnant women in determining whether Zika virus infection occurred during or before the pregnancy.

This report summarizes existing and new guidance on dengue and Zika virus diagnostic testing for patients with a clinically compatible illness who live in or recently traveled to an area where there is risk for infection with both viruses. CDC recommendations for screening of asymptomatic pregnant women with possible Zika virus exposure are unchanged. For symptomatic nonpregnant persons, dengue and Zika virus NAATs should be performed on serum collected ≤7 days after symptom onset. Dengue and Zika virus IgM antibody testing should be performed on NAAT-negative serum specimens or serum collected >7 days after onset of symptoms. For symptomatic pregnant women, serum and urine specimens should be collected as soon as possible within 12 weeks of symptom onset for concurrent dengue and Zika virus NAATs and IgM antibody testing. Positive IgM antibody test results with negative NAAT results should be confirmed by neutralizing antibody tests when clinically or epidemiologically indicated, including for all pregnant women. Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when deciding which tests to perform and for interpreting results.

Patients with clinically suspected dengue should receive appropriate management to monitor and treat shock and hemorrhage. Women with laboratory evidence of possible Zika virus infection during pregnancy and their infants should be evaluated and managed for possible adverse outcomes. Dengue and Zika virus disease are nationally notifiable conditions, and cases should be reported to public health authorities.

Introduction

Dengue and Zika viruses are closely related mosquitoborne flaviviruses with similar transmission cycles, distribution throughout the tropics, and disease manifestations (1,2). Although the four dengue viruses are the predominant flaviviruses transmitted by Aedes mosquitoes in the tropics and subtropics, the recent emergence of Zika virus has complicated diagnostic testing considerations and interpretation. For patients with suspected dengue or Zika virus disease, nucleic acid amplification tests (NAATs) are the preferred method of diagnosis because they can provide confirmed evidence of infection and distinguish the specific virus (3,4). Immunoglobulin M (IgM) and neutralizing antibody testing also can be used to identify dengue and Zika virus infections, particularly in patients who present after viral nucleic acid is no longer detectable (4–7). However, dengue and Zika virus antibody testing is complicated by cross-reactivity that might preclude conclusive determination of which flavivirus is responsible for the person’s recent infection (8). Moreover, because flavivirus IgM antibodies are often detectable for months after an infection, determining the specific timing of infection can be difficult, especially among persons who live in or frequently travel to areas with risk for dengue or Zika virus infection (5,9–11). These limitations are a particular challenge for pregnant women in determining whether Zika virus infection occurred during or before the pregnancy.

Previous guidance provided diagnostic testing recommendations for pregnant and nonpregnant persons with possible Zika virus infection (12–14). Existing CDC recommendations for screening of asymptomatic pregnant women with possible Zika virus exposure are unchanged (12). This report updates CDC’s diagnostic testing guidance for patients, including pregnant women, with an illness clinically compatible with dengue or Zika virus disease and who reside in or recently traveled to an area where there is risk for infection with both dengue and Zika viruses.
Purpose

These guidelines provide federal, state, territorial, and local health departments with recommended diagnostic algorithms and interpretation of test results for evaluation of dengue and Zika virus infection in patients with a clinically compatible illness and relevant epidemiologic exposure. These recommendations have incorporated lessons learned and feedback from public health and commercial laboratories regarding previously published guidelines (12,13,15,16). Because recommendations are intended for health departments, laboratories and health departments can adapt the recommendations according to local needs, resource availability, capacity for diagnostic testing, and epidemiologic conditions. Up-to-date information on areas where there is risk for dengue and Zika virus infection and ongoing outbreaks are available online (17,18).

Methods

A work group comprising CDC epidemiologists, physicians, and laboratorians was convened in January 2018. The group reviewed data regarding the natural history of dengue and Zika virus infections and the resulting immune response. In addition, they evaluated evidence on the performance of diagnostic tests to detect and differentiate dengue and Zika virus infections. Primary data sources included published peer-reviewed studies identified through searches of PubMed (n = 97) and Medline (n = 276) and references cited in relevant articles (n = 4). Unpublished data also were considered, including package inserts for products submitted to the U.S. Food and Drug Administration (FDA) for approval (n = 4) or Emergency Use Authorization (n = 19), and data derived from diagnostic testing performed at CDC (19). Evidence evaluated included the sensitivity and specificity of NAAT and IgM antibody assays by day postonset of illness, concordance of NAAT and serologic test results, and frequency of confirmation of IgM antibody detection with virus-specific neutralizing antibodies. Testing recommendations might be updated when additional assays have been evaluated and are approved for routine use by FDA.

Dengue and Zika Virus Epidemiology and Clinical Manifestations

Dengue and Zika viruses are transmitted by Aedes species mosquitoes, primarily Aedes aegypti, which are present throughout the tropics and subtropics (1,2). Infection with any of these viruses can result in an acute illness that includes fever, rash, myalgia, and arthralgia. Certain patients with dengue will progress to potentially fatal severe dengue, for which appropriate clinical management can reduce the case-fatality rate among hospitalized patients to <0.5% (20,21). The incidence of dengue has doubled each decade since 1990 such that, in 2013, an estimated 58 million symptomatic infections and 13,000 deaths occurred worldwide (2,22,23).

Zika virus was first isolated in Uganda in 1947. For the next 60 years, only sporadic cases were identified in Africa and Asia until 2007, when the first outbreak was recognized in Micronesia (24–27). During 2013–2015, approximately 30,000 suspected Zika virus disease cases were reported from French Polynesia and other Pacific islands. During 2015–2016, large outbreaks occurred throughout much of the Americas (1,28,29). During these recent outbreaks, new modes of transmission (e.g., congenital, perinatal, and sexual) and clinical manifestations (e.g., fetal loss, microcephaly, serious birth defects of the brain and eye, Guillain-Barre syndrome, other neurologic syndromes, and severe thrombocytopenia) (1,29,30) were identified.

Dengue and Zika Virus Infections and Immune Response

Most dengue and Zika virus infections are asymptomatic (2,27,31). Among symptomatic persons, the incubation period from infection until disease onset is a few days to 2 weeks (32–34). Dengue and Zika virus RNA are likely to be detected in serum from approximately 2 days before to 1 week after illness onset (4,5,35,36). However, detection of Zika virus nucleic acid might be prolonged in some patients, especially pregnant women (5,37–41). Zika virus RNA also can be detected in other body fluids (e.g., whole blood, urine, saliva, amniotic fluid, semen, and breast milk), and some reports suggest that viral RNA might be found at higher levels or for longer duration in some of these specimens (7,42–48). Dengue virus nonstructural protein-1 (NS1) antigen also can be detected in serum with similar frequency and duration as dengue viral RNA (35).

IgM antibodies directed against dengue and Zika virus typically develop during the first week of illness (4,5,7); however, limited published data exist on the duration of IgM antibodies following dengue or Zika virus infection. Among adults with dengue virus infection in Taiwan, 71% (31 of 44) had IgM antibodies against the envelope protein detectable at 6 months after acute infection, and 46% (20 of 44) had detectable IgM at 12 months after onset (49). Among 266 patients from Brazil with confirmed dengue virus infection, >70% had IgM antibody against the NS1 protein detected for >90 days after illness onset (49,50). In one study of patients...
with symptomatic Zika virus infection, 87% (52 of 60) had detectable IgM antibodies >60 days after symptom onset (5). In another cohort study of persons confirmed with Zika virus infection, 73% (45 of 62) had detectable IgM antibodies at 12–19 months after acute illness (51). Data for closely related flaviviruses (i.e., West Nile and yellow fever viruses) indicate that IgM antibodies might be detectable in serum for months or years after initial infection (9–11).

Neutralizing antibodies develop shortly after IgM antibodies and consist primarily of IgG antibodies. Neutralizing antibodies persist for multiple years after flavivirus infections and usually confer long-lived immunity (52–54). In persons previously infected with or vaccinated against a flavivirus, subsequent infection with another flavivirus (i.e., secondary flavivirus infection) can result in both a diminished IgM response and a rapid increase in neutralizing antibodies against multiple flaviviruses, which might preclude conclusive determination of which virus was responsible for the person’s recent infection (4,50,55–59).

**Dengue and Zika Virus Diagnostic Testing**

Dengue and Zika virus diagnostic testing employs both molecular and serologic methods; testing for dengue virus also includes detection of NS1 antigen. For patients with suspected dengue or Zika virus disease, molecular testing can provide confirmed evidence of infection, and NAATs can distinguish the specific virus. However, despite the high sensitivity and specificity of NAAT, both false-negative and false-positive results can occur (3,60–64).

With IgM antibody testing, false-positive results are more common than with NAAT and can occur because of nonspecific reactivity or cross-reactivity with other flaviviruses (e.g., West Nile, St. Louis encephalitis, Japanese encephalitis, or yellow fever viruses) (4,6,8). In addition, because IgM antibodies might be detectable for months or longer after infection, determining the specific timing of dengue and Zika virus infection can be difficult, especially among persons who live in or frequently travel to areas where the disease is endemic. These limitations of serologic testing are a particular challenge for pregnant women and attempts to determine whether Zika virus infection might have occurred during or before pregnancy. With decreased incidence and thus lower likelihood of Zika virus infection, a higher proportion of positive IgM antibody tests will be due to cross-reactivity with dengue or other flavivirus antibodies, a previous Zika virus infection, or false-positive results.

Plaque reduction neutralization tests (PRNTs) are quantitative assays that measure virus-specific neutralizing antibody titers for dengue, Zika, and other flaviviruses to which the patient might have been exposed (56,65). For diagnostic testing, CDC uses a PRNT with a 90% cutoff value titer ≥10 in serum and ≥2 in cerebrospinal fluid (the typical starting dilutions) to define positive specimens. PRNTs can resolve false-positive IgM antibody results caused by nonspecific reactivity and, in certain cases, can help identify the infecting virus. In primary flavivirus infections, a neutralizing antibody titer ≥4-fold higher than titers against other flaviviruses to which the person might have been exposed usually determines the specific infecting flavivirus. Recent findings indicate that neutralizing antibody titers might be able to differentiate dengue and Zika virus infections, particularly in specimens collected ≥3 months after illness onset (66). However, at 12–19 months after confirmed Zika virus infection, 17 (27%) of 62 persons in Florida still had neutralizing antibody titers that could not distinguish between dengue and Zika viruses (51). On the basis of previous flavivirus research and limited data specific to dengue and Zika viruses, the historic use of a four-fold higher titer by PRNT might not discriminate between dengue and Zika virus antibodies during the acute illness, especially following secondary flavivirus infections (8,56,57,66). Consequently, in areas with high prevalence of dengue and Zika virus infections, PRNT might not define the infecting virus for a significant proportion of cases (8). Therefore, such jurisdictions should make informed decisions about the utility of PRNT depending on the prevalence of dengue and Zika virus infection and observed performance of PRNT to confirm IgM test results.

Most state health departments and numerous commercial laboratories perform dengue and Zika virus diagnostic testing, and confirmatory testing is available through multiple state health departments and CDC. FDA has cleared three assays for the diagnosis of dengue: 1) a NAAT for use on serum and whole blood, 2) an enzyme immunoassay that detects dengue virus NS1 antigen in serum, and 3) an enzyme immunoassay that detects dengue virus IgM antibodies in serum (63,66,67). FDA has cleared one enzyme immunoassay to detect Zika virus IgM antibodies in serum (68). FDA also has issued Emergency Use Authorizations for multiple NAAT and other IgM antibody assays to diagnose Zika virus infection (19). Various Zika virus NAATs can be used on serum, plasma, whole blood, cerebrospinal fluid, urine, or amniotic fluid. Zika virus IgM antibody assays can be used variably on serum, plasma, whole blood, or cerebrospinal fluid. Efforts are ongoing to develop and validate serologic assays to reliably differentiate dengue and Zika virus infections and to distinguish recent and previous infections (69).
During a dengue outbreak, jurisdictions might elect to forego Zika virus testing in nonpregnant persons with suspected dengue. Similarly, during a Zika virus outbreak, jurisdictions might elect to forego dengue virus testing in nonpregnant persons with suspected Zika virus disease. In both scenarios, because of possible adverse outcomes, pregnant women should be tested by NAAT for evidence of infection with both dengue and Zika viruses and by serology for evidence of infection with the virus causing the outbreak. Patients for whom testing is unable to determine the infecting flavivirus should be clinically managed for possible dengue and, in pregnant patients, Zika virus infection because they might have been infected with either virus.

**Clinical and Epidemiologic Criteria for Testing**

Dengue and Zika virus testing should be considered in a patient with a clinically compatible illness who lives in or recently traveled to an area where there is risk for infection with these viruses. Zika virus testing also should be considered in symptomatic patients who had sex with someone who lives in or recently traveled to those areas (17,18).

The U.S. surveillance case definitions for dengue and Zika virus disease include both clinical and diagnostic testing criteria. The case definition for dengue includes fever with one or more other characteristic finding (i.e., nausea, vomiting, rash, headache, retro-orbital pain, myalgia, arthralgia, positive tourniquet test, leukopenia, or a dengue warning sign) (70). For Zika virus disease, the surveillance case definition requires a clinically compatible illness with fever, rash, arthralgia, or conjunctivitis (71). For patients who live in or recently traveled to areas where there is risk for dengue and Zika virus infection, the broader clinical findings (i.e., fever, rash, arthralgia, or conjunctivitis) should be taken into account when considering testing for possible infection with either virus. Other infectious etiologies to consider in the differential diagnosis include chikungunya, malaria, rubella, measles, hepatitis A, parvovirus, adenovirus, enterovirus, leptospirosis, rickettsiosis, and group A streptococcal infections.

Pregnant women face potential complications from infection with either dengue or Zika virus (72). Dengue virus infection might increase the risk for maternal death or obstetric complications (e.g., hemorrhage, preeclampsia, eclampsia, and vertical transmission) during the peripartum period (73–75). Zika virus infection during pregnancy can result in fetal loss, microcephaly, or serious birth defects including structural abnormalities of the brain and eye (30,72).

**Recommended Testing for Symptomatic Nonpregnant Patients**

For nonpregnant persons with a clinically compatible illness, dengue and Zika virus NAATs should be performed on serum collected ≤7 days after symptom onset (Figure 1). Various NAATs also can be performed on plasma, whole blood, cerebrospinal fluid, or urine. For symptomatic persons with possible exposure to dengue and Zika virus, a positive NAAT result typically provides evidence of acute infection, and no antibody testing is indicated (Table). However, patients for whom the diagnosis has epidemiologic or clinical significance (e.g., first local transmission in area, new transmission mode, patient has an unusual clinical syndrome, or diagnosis will affect clinical management), a repeat NAAT should be performed on newly extracted RNA from the same specimen to rule out false-positive test results.

Because of the decline in the level of viremia over time and possible inaccurate reporting of dates of illness onset, a negative NAAT result does not exclude dengue or Zika virus infection. Therefore, dengue and Zika virus IgM antibody testing should be performed on NAAT-negative serum specimens and serum collected >7 days after onset of symptoms. Certain IgM antibody assays also can be used on plasma, whole blood, or cerebrospinal fluid. Some laboratories might choose to perform dengue and Zika virus NAATs and IgM antibody testing simultaneously rather than sequentially.

For serum specimens collected <7 days after onset of symptoms, the combination of a negative NAAT result and negative IgM antibody testing suggests the patient did not have a recent flavivirus infection. However, in the absence of NAAT testing, a negative acute IgM antibody test might reflect specimen collection before development of detectable antibodies and does not rule out infection. For specimens collected from 7 days to 12 weeks after onset of symptoms, a negative IgM antibody result to both dengue and Zika virus rules out recent infection with either virus, and testing for other etiologies should be considered.

If either dengue or Zika virus IgM antibody testing is positive without a positive NAAT or NS1 antigen test, and definitive diagnosis is needed for clinical or epidemiologic purposes, confirmatory PRNTs should be performed against dengue, Zika, and other flaviviruses endemic to the region where exposure occurred. For indeterminate IgM antibody results, IgM antibody testing should be repeated on the same specimen or PRNTs performed. In the setting of positive IgM antibody testing, a PRNT titer ≥10 against dengue virus with negative PRNTs (i.e., <10) against Zika and other flaviviruses.
FIGURE 1. Dengue and Zika virus testing recommendations for nonpregnant persons with a clinically compatible illness and risk for infection with both viruses*

Abbreviations: IgM = immunoglobulin M; NAAT = nucleic acid amplification test; PRNT = plaque reduction neutralization test.

* Specimen and test selection: Dengue and Zika virus NAATs, IgM antibody testing, and PRNTs should be performed on serum. Some NAATs also can be performed on plasma, whole blood, cerebrospinal fluid, or urine, and some antibody tests can be performed on plasma, whole blood, or cerebrospinal fluid. Laboratories might choose to perform dengue and Zika virus NAATs and IgM antibody testing simultaneously rather than sequentially, or to perform dengue virus nonstructural protein-1 testing instead of dengue virus NAAT.

Indications to repeat assay(s): If the patient's illness has epidemiologic or clinical significance (e.g., first case of local transmission in area, new transmission mode, or unusual clinical syndrome), repeat a positive NAAT on newly extracted RNA from the same specimen. For indeterminate IgM antibody test results, repeat IgM antibody testing or perform PRNT on the same specimen. In areas where PRNTs are not performed, report the indeterminate results and request a second serum specimen for IgM antibody testing.

Interpretation of results: Dengue and Zika virus IgM antibodies can be detected in serum for months following infection. The specific timing of infection cannot be determined. Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when interpreting the results of serologic diagnostic testing.

is considered evidence of recent dengue virus infection (Table). Conversely, a PRNT titer ≥10 against Zika virus with negative PRNTs against dengue and other flaviviruses is evidence of recent Zika virus infection. A PRNT titer ≥10 for both Zika and dengue virus (or another flavivirus) provides evidence of a recent infection with a flavivirus but precludes identification of the specific infecting virus or timing of infection on the basis of laboratory testing alone.

Negative PRNT titers against dengue and Zika virus in a serum specimen collected >7 days after illness onset rule out infection with either virus (Table). Without confirmatory PRNTs, determining whether positive IgM antibody results reflect a recent flavivirus infection or a false-positive result is not possible. In areas where PRNTs are not performed, positive dengue and negative Zika virus IgM antibody tests should be interpreted as a “presumptive recent dengue virus infection,” positive Zika and negative dengue virus IgM antibody tests should be interpreted as a “presumptive recent Zika virus infection,” and positive dengue and Zika virus IgM antibody tests should be interpreted as a “presumptive recent flavivirus infection.” If only one IgM antibody test was performed and was positive and PRNT was not performed, the second IgM test should be performed. If it is not possible to perform the second test, results of the first test should be interpreted as a “presumptive recent flavivirus infection.”

For nonpregnant patients who live in or recently returned from an area where there is an ongoing outbreak in which only one virus has been detected to be circulating, jurisdictions
**TABLE. Interpretation of dengue and Zika virus diagnostic test results for patients with a clinically compatible illness and risk for infection with both viruses**

| Dengue and Zika virus NAATs | Interpretation |
|-----------------------------|----------------|
| Positive dengue virus assay, negative Zika virus assay | Acute dengue virus infection |
| Positive Zika virus assay, negative dengue virus assay | Acute Zika virus infection |
| Positive (both assays) | Acute dengue and Zika virus co-infection |
| Negative (both assays) | No evidence of dengue or Zika virus infection* |

**Dengue and Zika virus IgM antibodies**

| Dengue virus PRNT | Zika virus PRNT | Nonpregnant patients | Pregnant women |
|-------------------|----------------|---------------------|----------------|
| Positive (either assay)†,§ | ≥10 | <10 | Recent dengue virus infection |
| Positive (either assay)†,§ | <10 | ≥10 | Recent Zika virus infection |
| Positive (either assay)† | ≥10 | ≥10 | Recent flavivirus infection§ |
| Any result | <10 | <10 | No evidence of dengue or Zika virus infection** |

**Recommendations and Reports**

Pregnant women with a clinically compatible illness and recent possible exposure to dengue and Zika virus should have concurrent diagnostic testing for dengue and Zika virus infection performed by NAAT and IgM antibody testing on a serum specimen and NAAT on a urine specimen to diagnose Zika virus infection (Figure 2). Specimens should be collected as soon as possible for dengue and Zika virus NAATs and within 12 weeks of symptom onset for Zika virus NAAT. Various NAATs also can be performed on plasma, whole blood, cerebrospinal fluid, or amniotic fluid;
FIGURE 2. Dengue and Zika virus testing recommendations for pregnant persons with a clinically compatible illness and risk for infection with both viruses*

| Specimen collected ≤12 weeks postsymptom onset |
|------------------------------------------------|
| Perform dengue and Zika virus NAATs and dengue and Zika virus IgM serology |

| Positive dengue virus NAAT | Positive Zika virus NAAT |
|----------------------------|-------------------------|
| Negative dengue and Zika virus NAATs and positive dengue or Zika virus IgM |
| Negative dengue and Zika virus NAATs and negative dengue or Zika virus IgM |

| Perform dengue and Zika virus PRNTs |
|---------------------------------|
| Dengue virus PRNT ≥10 and Zika virus PRNT <10 |
| Dengue virus PRNT <10 and Zika virus PRNT ≥10 |
| Dengue virus PRNT ≥10 and Zika virus PRNT ≥10 |
| Dengue virus PRNT <10 and Zika virus PRNT <10 |

| Acute dengue virus infection | Acute Zika virus infection | Dengue virus infection | Zika virus infection | Flavivirus infection | No evidence of dengue or Zika virus infection |

**Abbreviations:** IgM = immunoglobulin M; NAAT = nucleic acid amplification test; PRNT = plaque reduction neutralization test.

* Specimen and test selection: Dengue and Zika virus NAATs, IgM antibody testing, and PRNTs should be performed on serum. Some NAATs also can be performed on plasma, whole blood, cerebrospinal fluid, or urine, and some antibody tests can be performed on plasma, whole blood, or cerebrospinal fluid. Dengue virus NAAT does not need to be performed on specimens collected >7 days after illness onset. Some laboratories might choose to perform dengue virus nonstructural protein-1 testing instead of dengue virus NAAT.

**Indications to repeat assay(s):** If Zika virus NAAT is positive on a single specimen but IgM antibody tests are negative, repeat NAAT on newly extracted RNA from the same specimen. For indeterminate IgM antibody test results, repeat IgM antibody testing or perform PRNT on the same specimen. In areas where PRNTs are not performed, report the indeterminate results and request a second serum specimen for IgM antibody testing.

**Interpretation of results:** Dengue and Zika virus IgM antibodies can be detected in serum for months following infection. The specific timing of infection cannot be determined. Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when interpreting the results of serologic diagnostic testing.

IgM antibody testing can be performed on plasma, whole blood, or cerebrospinal fluid. A positive NAAT result on any specimen typically provides evidence of recent infection. However, if NAAT is only positive for Zika virus on a single specimen and IgM antibody testing is negative, the NAAT should be repeated on newly extracted RNA from the same specimen to rule out false-positive test results.

If both dengue and Zika virus NAATs are negative but either IgM antibody test is positive, confirmatory PRNTs should be performed against dengue, Zika, and other flaviviruses endemic to the region where exposure occurred. For indeterminate IgM antibody results, IgM antibody testing should be repeated on the same specimen or PRNTs performed. If IgM antibody results are positive for one virus but the assay for the other virus was not performed, the second assay should be performed to appropriately interpret results. If the second assay is not performed, the single positive result should be interpreted as “presumptive flavivirus infection.” The interpretation for IgM and neutralizing antibody test results in a symptomatic pregnant woman is similar to that for nonpregnant patients; however, because dengue and Zika virus IgM antibodies can be detected in serum for months after an infection, the specific timing of infection cannot be determined, and other factors (e.g., epidemiologic and clinical findings) should be used to assess the likelihood that the current illness was due to either dengue or Zika virus and that exposure occurred during the pregnancy (Table). Pregnant women living in or returning from an area where there is an ongoing outbreak in which only one virus has been detected to be circulating should be tested by NAAT for evidence of infection with both dengue and Zika.
viruses; however, jurisdictions might elect to perform serologic diagnostic testing solely for the virus causing the outbreak.

Zika virus testing recommendations for asymptomatic pregnant women are unchanged (12). For asymptomatic pregnant women without ongoing risk for possible Zika virus infection, testing for Zika virus infection is not routinely recommended. However, testing should be considered using a shared decision-making model, in which patients and providers work together to make decisions about testing and care plans on the basis of patient preferences and values, clinical judgment, a balanced assessment of risks and expected outcomes, and the jurisdiction's recommendations.

Management of Patients with Dengue or Zika Virus Infection

Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered in clinical and testing decisions and when interpreting results (17,18). All patients with clinically suspected dengue should receive appropriate management to monitor for shock and reduce the risk for complications resulting from plasma leakage and organ damage without waiting for diagnostic test results to be received (20). Women with laboratory evidence of possible Zika virus infection during pregnancy and their infants should be evaluated and managed for possible adverse outcomes, including congenital Zika virus infection (12,76). Patients for whom testing is unable to determine the most recent infecting flavivirus should be clinically managed for possible dengue and, in pregnant patients, Zika virus infection because they might have been infected with either virus. Health care providers with questions about test result interpretation should consult with state or local public health authorities for assistance.

Reporting Dengue and Zika Virus Disease Cases

Dengue and Zika virus disease are nationally notifiable conditions. Health care providers are encouraged to report suspected dengue and Zika virus disease cases to their state, territorial, or local health departments to facilitate diagnosis and mitigate the risk for local transmission. State and territorial health departments should report cases to CDC according to the Council of State and Territorial Epidemiologists case definitions (70,71).

Conflict of Interest

No conflicts of interest were reported.

References

1. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med 2016;374:1552–63. https://doi.org/10.1056/NEJMra1602113
2. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med 2012;366:1423–32.
3. Santiago GA, Vázquez J, Courtney S, et al. Performance of the Trioplex real-time RT-PCR assay for detection of Zika, dengue, and chikungunya viruses. Nat Commun 2018;9:1391. https://doi.org/10.1038/s41467-018-03772-1
4. Lanciotti RS, Kosoy DL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic. Yap State, Micronesia, 2007. Emerg Infect Dis 2008;14:1232–9. https://doi.org/10.3201/eid1408.080287
5. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids—final report. N Engl J Med 2018;379:1234–43. https://doi.org/10.1056/NEJMoa1613108
6. Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 2000;38:1823–6.
7. Bingham AM, Cone M, Mock V, et al. Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika virus disease—Florida, 2016. MMWR Morb Mortal Wkly Rep 2016;65:475–8. https://doi.org/10.15585/mmwr.mm6518e2
8. Lindsey NP, Staples JE, Powell K, et al. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and U.S. territories in 2016. J Clin Microbiol 2017;55:1115–7.
9. Prince HE, Tobler LH, Yeh C, Gefter N, Custer B, Busch MP. Persistence of West Nile virus-specific antibodies in viremic blood donors. Clin Vaccine Immunol 2007;14:1228–30. https://doi.org/10.1128/CVI.00233-07
10. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003;9:376–9. https://doi.org/10.3201/eid0903.020531
11. Gibney KB, Edupuganti S, Panella AJ, et al. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3–4 years following yellow fever vaccination. Am J Trop Med Hyg 2012;87:1112–5. https://doi.org/10.4269/ajtmh.2012.12-0182
12. Oduyebó T, Polen KD, Walke HT, et al. Update: Interim guidance for healthcare providers caring for pregnant women with possible Zika virus exposure—United States (including U.S. territories), July 2017. MMWR Morb Mortal Wkly Rep 2017;66:781–93. https://doi.org/10.15585/mmwr.mm6629e1
13. Rabe IB, Staples JE, Villanueva J, et al. MTS. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 2016;65:543–6. https://doi.org/10.15585/mmwr.mm6521e1
14. CDC. Testing guidance. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/zika/hc-providers/testing-guidance.html
15. Petersen EE, Staples JE, Meaney-Delman D, et al. Interim guidelines for pregnant women during a Zika virus outbreak—United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:30–3. https://doi.org/10.15585/mmwr.mm6502e1
16. Oduyebó T, Igbinosa I, Petersen EE, et al. Update: Interim guidance for healthcare providers caring for pregnant women with possible Zika virus exposure—United States, July 2016. MMWR Morb Mortal Wkly Rep 2016;65:739–44. https://doi.org/10.15585/mmwr.mm6529e1
17. CDC. Zika in the US. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/zika/geo/index.html
18. HealthMap. DengueMap. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.healthmap.org/dengue/en/index.php
19. US Food and Drug Administration. Emergency use authorizations; Silver Spring, MD: US Department of Health and Human Services; 2019. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#zika
20. World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control: new edition. Geneva, Switzerland: World Health Organization; 2009.
21. Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis 2013;57:1577–86. https://doi.org/10.1093/cid/cir594
22. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis 2016;16:935–41. https://doi.org/10.1016/S1473-3099(16)00146-8
23. Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:712–23. https://doi.org/10.1016/S1473-3099(16)00026-8
24. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and persistence in Aedes aegypti and Aedes albopictus. Ann Trop Med Publ Health 1975;69:49–64. https://doi.org/10.1086/34983.1975.11668983
25. Olson JG, Ksiazek TG, Gubler DJ, et al. A survey for arboviral antibodies in sera of humans and animals in Lombok, Republic of Indonesia. Ann Trop Med Parasitol 1983;77:131–7. https://doi.org/10.1080/00034983.1983.11811687
26. Moore DL, Causey OR, Carey DE, et al. Arthropod-borne viral infections of man in Nigeria, 1964–1970. Ann Trop Med Parasitol 1975;69:49–64. https://doi.org/10.1080/34983.1975.11668983
27. Rassmusen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 2009;360:2536–43. https://doi.org/10.1056/NEJMoa0805715
28. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 2014;20:1085–6. https://doi.org/10.3201/eid2011.141380
29. Hills SL, Fischer M, Petersen LR. Epidemiology of Zika virus infection. J Infect Dis 2017;216(suppl_10):S686–74.
30. Leslser J, Ort CT, Carcelen AC, et al. Times to key events in Zika virus infection and implications for blood donation: a systematic review. Bull World Health Organ 2016;94:841–9. https://doi.org/10.1093/bulletin/1674540
31. Choi YW, Liu ZH, Tseng FC, et al. Prolonged persistence of IgM and IgG antibodies against dengue virus detected by commonly used commercial assays. J Clin Virol 2016;77:69–70. https://doi.org/10.1016/j.jcv.2015.04.021
32. Krow-Lucal ER, Biggerstaff BJ, Staples JE. Estimated incubation period for Zika virus infection and implications for blood donation: a systematic review. Bull World Health Organ 2016;94:841–9. https://doi.org/10.1093/bulletin/1674540
33. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 2014;20:1085–6. https://doi.org/10.3201/eid2011.141380
34. Busch MP, Kleinman SH, Tobler LH, et al. Zika virus RNA in urine samples during the ongoing Zika virus epidemic in Brazil. J Clin Virol 2016;77:69–70. https://doi.org/10.1016/j.jcv.2016.02.009
35. Busch MP, Kleinman SH, Tobler LH, et al. Zika virus RNA in urine samples during the ongoing Zika virus epidemic in Brazil. J Clin Virol 2016;77:69–70. https://doi.org/10.1016/j.jcv.2016.02.009
36. Musso D, Nhan TX, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014;19(14). pii: 20761. PubMed PMID: 24739982. Erratum in: Euro Surveill 2014;19(15):pii:pi120771.
55. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 2005;43:4977–83. https://doi.org/10.1128/JCM.43.10.4977-4983.2005

56. Calisher CH, Karabatsos N, Dalrymple JM, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 1989;70:37–43. https://doi.org/10.1099/0022-1317-70-1-37

57. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg 1983;32:154–6. https://doi.org/10.4269/ajtmh.1983.32.154

58. Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010;8(Suppl):S30–8. https://doi.org/10.1038/nrmicro2459

59. Hunsperger EA, Yoksan S, Buchy P, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. PLoS Negl Trop Dis 2014;8:e3171. https://doi.org/10.1371/journal.pntd.0003171

60. Galel SA, Williamson PC, Busch MP, et al; cobas Zika IND Study Group. First Zika-positive donations in the continental United States. Transfusion 2017;57(3pt2):762–9. https://doi.org/10.1111/trf.14029

61. Saá P, Proctor M, Foster G, et al. Investigational testing for Zika virus among U.S. blood donors. N Engl J Med 2018;378:1778–88. https://doi.org/10.1056/NEJMoa1714977

62. Williamson PC, Linnen JM, Kessler DA, et al. First cases of Zika virus-infected US blood donors outside states with areas of active transmission. Transfusion 2017;57(3pt2):770–8. https://doi.org/10.1111/trf.14041

63. InBios. DENV Detect™NS1 ELISA Kit. Seattle, WA: InBios; 2004–2017. https://inbios.com/denv-detect-ns1-elisa-usa/

64. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008;21:123–32. https://doi.org/10.1089/vim.2008.0007

65. Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal analysis of antibody cross-neutralization following Zika and dengue virus infection in Asia and the Americas. J Infect Dis 2018;218:536–45. https://doi.org/10.1093/infdis/jiy164

66. Santiago GA, Vergne E, Quiles Y, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. PLoS Negl Trop Dis 2013;7:e2311. https://doi.org/10.1371/journal.pntd.0002311

67. InBios. DENV Detect™IgM Capture ELISA Kit. Seattle, WA: InBios; 2004–2017. https://inbios.com/denvdetecttm-igm-capture-kit-usa/

68. InBios. ZIKV Detect™ 2.0 IgM Capture ELISA Kit. Seattle, WA: InBios; 2004–2017. https://inbios.com/zikv-detecttm-igm-capture-elsa-kit-usa/

69. Goncalves A, Peeling RW, Chu MC, et al. Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report. J Infect Dis 2018;217:1060–8. https://doi.org/10.1093/infdis/jix678

70. CDC. Dengue virus infections, 2015 case definition. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://wwwnc.cdc.gov/nndss/conditions/dengue-virus-infections/case-definition/2015/

71. CDC. Zika virus disease and Zika virus infection, 2016 case definition. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.

72. Charlier C, Beaudoin MC, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy: maternal, fetal, and neonatal effects. Lancet Child Adolesc Health 2017;1:134–46. https://doi.org/10.1016/S2352-4642(17)30021-4

73. Machado CR, Machado ES, Rohloff RD, et al. Is pregnancy associated with severe dengue? A review of data from the Rio de Janeiro surveillance information system. PLoS Negl Trop Dis 2013;7:e2217. https://doi.org/10.1371/journal.pntd.0002217

74. Paixao ES, Harron K, Campbell O, et al. Dengue in pregnancy and maternal mortality: a cohort analysis using routine data. Sci Rep 2018;8:9938. https://doi.org/10.1038/s41598-018-28387-w

75. Machain-Williams C, Raga E, Baak-Baak CM, Kiem S, Blirvich BJ, Ramos C. Maternal, fetal, and neonatal outcomes in pregnant dengue patients in Mexico. BioMed Res Int 2018;2018:9643083. https://doi.org/10.1155/2018/9643083

76. Adebanjo T, Godfred-Cato S, Viens L, et al; Contributors. Update: interim guidance for the diagnosis, evaluation, and management of infants with possible congenital Zika virus infection—United States, October 2017. MMWR Morb Mortal Wkly Rep 2017;66:1089–99. https://doi.org/10.15585/mmwr.mm6641a1
